免疫グロブリンA（IgA）血管炎の世界市場レポート2025年

免疫グロブリンA（IgA）血管炎の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で20億8,000万米ドルに成長します。予測期間の成長は、先進的バイオマーカーの使用増加、併存疾患の罹患率上昇、臨床検査数の増加、生物学的療法への関心の高まり、低侵襲治療オプションの需要拡大に起因すると考えられます。主要動向としては、精密医療の統合、免疫抑制療法の革新、疾患修飾療法の開発、早期診断のためのバイオマーカーの進歩、治療計画への人工知能の導入などが挙げられます。

自己免疫疾患の罹患率の上昇は、免疫グロブリンA（IgA）血管炎市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が感染症を防御する代わりに、身体自身の健康な細胞、組織、臓器を誤って攻撃することで発症します。これらの疾患の有病率の増加は、免疫調節を乱し、異常な免疫反応を引き起こす可能性のある環境汚染物質へのさらなる曝露が主要原因です。IgA血管炎は、細い血管に炎症を起こすことで自己免疫疾患の一翼を担っており、様々な自己免疫疾患の理解と治療に役立つ知見を提供しています。例えば、2024年11月、ドイツを拠点とする組織であるVersorgungsatlas.deのデータによると、2022年の保険加入者7,324万1,305人のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、生の有病率は8.61％に相当します。したがって、この罹患率の上昇がIgA血管炎市場の成長を後押ししています。

標的療法への注目の高まりが免疫グロブリンA（IgA）血管炎市場の成長を促進すると予想されます。標的治療とは、疾患に関与する分子異常を特異的に阻害するように設計された治療法で、これにより治療精度が向上し、健康な細胞へのダメージが最小限に抑えられます。標的治療が重視されるようになった背景には、個人の遺伝的プロファイルに基づいて治療を調整し、より高い効果を得る精密医療の進歩があります。IgA血管炎では、標的療法は特定の免疫経路に焦点を当て、全身的な副作用を軽減し、炎症を抑え、臓器障害を予防し、最終的に患者の転帰とQOLを向上させています。例えば、2024年12月、米国遺伝子細胞治療学会（ASGCT）は、FDAが2023年に6つの遺伝子治療製品を承認したと報告しました。したがって、標的治療への注目の高まりが免疫グロブリンA血管炎市場を前進させています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 全身性免疫グロブリンA（IgA）血管炎：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の免疫グロブリンA（IgA）血管炎市場の成長率分析
• 世界の免疫グロブリンA（IgA）血管炎の市場規模実績と成長、2019～2024年
• 世界の免疫グロブリンA（IgA）血管炎の市場規模と成長予測、2024～2029年、2034年
• 全身性免疫グロブリンA（IgA）血管炎：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の免疫グロブリンA（IgA）血管炎市場、治療タイプ別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 医薬品
• 血漿交換
• 支持療法
• 免疫抑制療法
• 免疫グロブリンA（IgA）血管炎の世界市場、診断方法別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 血液検査
• 尿検査
• 画像研究
• 生検
• 世界の免疫グロブリンA（IgA）血管炎市場：投与経路別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射剤
• 静脈内
• 世界の免疫グロブリンA（IgA）血管炎市場：エンドユーザー別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 在宅ケア
• 世界の免疫グロブリンA（IgA）血管炎市場、医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• コルチコステロイド
• 免疫抑制剤
• シクロホスファミド
• アザチオプリン
• ミコフェノール酸モフェチル
• 世界の免疫グロブリンA（IgA）血管炎市場、血漿交換のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 治療的血漿交換
• プラズマ濾過
• 世界の免疫グロブリンA（IgA）血管炎市場、支持療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 疼痛管理
• 腎機能サポート
• 血圧管理
• 世界の免疫グロブリンA（IgA）血管炎市場、免疫抑制療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• メトトレキサート
• リツキシマブ
• シクロホスファミド

第7章 地域別・国別分析

• 世界の免疫グロブリンA（IgA）血管炎市場：地域別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の免疫グロブリンA（IgA）血管炎市場：国別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫グロブリンA（IgA）血管炎市場の競合情勢
• 免疫グロブリンA（IgA）血管炎市場における企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Indraprastha Medical Corporation Limited
• Intas Pharmaceuticals Ltd
• Mayo Clinic
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• The Cleveland Clinic Foundation
• Zydus Lifesciences Limited
• CSL Behring
• Artemis Medicare Services Limited
• Biocad BIoTechnology Company
• BIoTest AG
• Kauvery Hospitals Private Limited
• Sheikh Shakhbout Medical City
• Reliance Life Sciences Pvt. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 2029年の免疫グロブリンA（IgA）血管炎市場-最も新たな機会を提供する国
• 2029年の免疫グロブリンA（IgA）血管炎市場-最も新たな機会を提供するセグメント
• 免疫グロブリンA（IgA）血管炎市場：、2029年-成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Immunoglobulin A (IgA) vasculitis is an autoimmune disorder marked by inflammation of small blood vessels caused by deposits of IgA antibodies. It primarily affects the skin, joints, kidneys, and gastrointestinal tract, manifesting as purplish rashes, abdominal pain, and joint inflammation.

The main treatment approaches for IgA vasculitis include medications, plasma exchange, supportive care, and immunosuppressive therapy. Medications are mainly aimed at reducing inflammation and managing symptoms such as joint pain, skin rash, and kidney issues resulting from immune reactions triggered by IgA deposits. Diagnosis typically involves blood tests, urinalysis, imaging, and tissue biopsy. Treatments are administered via oral, injectable, or intravenous routes and are provided in hospitals, specialty clinics, and homecare settings.

The immunoglobulin A (IgA) vasculitis market research report is one of a series of new reports from The Business Research Company that provides immunoglobulin A (IgA) vasculitis market statistics, including the immunoglobulin A (IgA) vasculitis industry's global market size, regional shares, competitors with the immunoglobulin A (IgA) vasculitis market share, detailed immunoglobulin A (IgA) vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin A (IgA) vasculitis market. This immunoglobulin A (IgA) vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunoglobulin A (IgA) vasculitis market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to increasing awareness of IgA vasculitis, a rising incidence of autoimmune diseases, greater use of immunosuppressive therapies, increased research funding for rare diseases, and growing adoption of targeted treatment options.

The immunoglobulin A (IgA) vasculitis market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the increasing use of advanced biomarkers, rising incidence of comorbid conditions, a growing number of clinical trials, heightened interest in biologic therapies, and expanding demand for minimally invasive treatment options. Major trends include the integration of precision medicine, innovations in immunosuppressive therapies, development of disease-modifying treatments, advancements in biomarkers for early diagnosis, and the incorporation of artificial intelligence in treatment planning.

The rising incidence of autoimmune diseases is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells, tissues, or organs instead of defending against infections. The increasing prevalence of these disorders is largely attributed to greater exposure to environmental pollutants, which can disrupt immune regulation and trigger abnormal immune responses. IgA vasculitis plays a role in autoimmune diseases by causing inflammation in small blood vessels, providing insights that may aid in understanding and treating various autoimmune conditions. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, corresponding to a raw prevalence rate of 8.61%. Therefore, this rising incidence is propelling the growth of the IgA vasculitis market.

The rising focus on targeted therapies is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Targeted therapies are treatments designed to specifically inhibit molecular abnormalities involved in diseases, thereby improving treatment precision and minimizing damage to healthy cells. This growing emphasis on targeted therapies is largely fueled by advancements in precision medicine, which tailors treatments based on an individual's genetic profile for greater effectiveness. In IgA vasculitis, targeted therapies focus on specific immune pathways, reducing systemic side effects, lowering inflammation, and preventing organ damage-ultimately enhancing patient outcomes and quality of life. For example, in December 2024, the American Society of Gene and Cell Therapy (ASGCT) reported that the FDA approved six gene therapy products in 2023, up from five approvals in 2022, reflecting increased innovation in targeted treatments. Therefore, this rising focus on targeted therapies is propelling the immunoglobulin A vasculitis market forward.

Leading companies in the immunoglobulin A (IgA) vasculitis market are concentrating on creating innovative treatments, including targeted biologics and immunomodulators, aimed at lowering inflammation and preventing kidney-related complications. These advanced therapies work by modulating specific immune pathways to decrease inflammation and protect against immune-driven damage in IgA vasculitis. For example, in April 2025, Novartis AG, a pharmaceutical firm based in Switzerland, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) to treat primary immunoglobulin A nephropathy (IgAN). Vanrafia is a selective endothelin A receptor antagonist taken orally once daily, intended to reduce proteinuria in adults with primary IgAN who face a high risk of rapid disease progression. It can be added to current supportive care plans without requiring a risk evaluation and mitigation strategy (REMS).

Major players in the immunoglobulin A (IgA) vasculitis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Indraprastha Medical Corporation Limited, Intas Pharmaceuticals Ltd, Mayo Clinic, Biogen Inc., Chugai Pharmaceutical Co. Ltd., The Cleveland Clinic Foundation, Zydus Lifesciences Limited, CSL Behring, Artemis Medicare Services Limited, Biocad Biotechnology Company, Biotest AG, Kauvery Hospitals Private Limited, Sheikh Shakhbout Medical City, and Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunoglobulin A (IgA) vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunoglobulin A (IgA) vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunoglobulin A (IgA) vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, renal function monitoring, patient management programs, and clinical research and trials for novel therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunoglobulin A (IgA) vasculitis market also includes sales of corticosteroids, pain relievers, diagnostic kits, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunoglobulin A IgA Vasculitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunoglobulin a iga vasculitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunoglobulin a iga vasculitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunoglobulin a iga vasculitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medications; Plasma Exchange; Supportive Care; Immunosuppressive Therapy
• 2) By Diagnosis Method: Blood Tests; Urinalysis; Imaging Studies; Biopsy
• 3) By Route Of Administration: Oral; Injectables; Intravenous
• 4) By End User: Hospitals; Specialty Clinics; Homecare Settings
• Subsegments:
• 1) By Medications: Corticosteroids; Immunosuppressants; Cyclophosphamide; Azathioprine; Mycophenolate Mofetil
• 2) By Plasma Exchange: Therapeutic Plasma Exchange; Plasma Filtration
• 3) By Supportive Care: Pain Management; Kidney Function Support; Blood Pressure Management
• 4) By Immunosuppressive Therapy: Methotrexate; Rituximab; Cyclophosphamide
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Novartis AG; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immunoglobulin A (IgA) Vasculitis Market Characteristics

3. Immunoglobulin A (IgA) Vasculitis Market Trends And Strategies

4. Immunoglobulin A (IgA) Vasculitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Immunoglobulin A (IgA) Vasculitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immunoglobulin A (IgA) Vasculitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immunoglobulin A (IgA) Vasculitis Market Growth Rate Analysis
• 5.4. Global Immunoglobulin A (IgA) Vasculitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immunoglobulin A (IgA) Vasculitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immunoglobulin A (IgA) Vasculitis Total Addressable Market (TAM)

6. Immunoglobulin A (IgA) Vasculitis Market Segmentation

• 6.1. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Plasma Exchange
• Supportive Care
• Immunosuppressive Therapy
• 6.2. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Urinalysis
• Imaging Studies
• Biopsy
• 6.3. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• Intravenous
• 6.4. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare Settings
• 6.5. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressants
• Cyclophosphamide
• Azathioprine
• Mycophenolate Mofetil
• 6.6. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Plasma Exchange, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic Plasma Exchange
• Plasma Filtration
• 6.7. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain Management
• Kidney Function Support
• Blood Pressure Management
• 6.8. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Immunosuppressive Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methotrexate
• Rituximab
• Cyclophosphamide

7. Immunoglobulin A (IgA) Vasculitis Market Regional And Country Analysis

• 7.1. Global Immunoglobulin A (IgA) Vasculitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immunoglobulin A (IgA) Vasculitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market

• 8.1. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immunoglobulin A (IgA) Vasculitis Market

• 9.1. China Immunoglobulin A (IgA) Vasculitis Market Overview
• 9.2. China Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immunoglobulin A (IgA) Vasculitis Market

• 10.1. India Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immunoglobulin A (IgA) Vasculitis Market

• 11.1. Japan Immunoglobulin A (IgA) Vasculitis Market Overview
• 11.2. Japan Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immunoglobulin A (IgA) Vasculitis Market

• 12.1. Australia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immunoglobulin A (IgA) Vasculitis Market

• 13.1. Indonesia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immunoglobulin A (IgA) Vasculitis Market

• 14.1. South Korea Immunoglobulin A (IgA) Vasculitis Market Overview
• 14.2. South Korea Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immunoglobulin A (IgA) Vasculitis Market

• 15.1. Western Europe Immunoglobulin A (IgA) Vasculitis Market Overview
• 15.2. Western Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immunoglobulin A (IgA) Vasculitis Market

• 16.1. UK Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immunoglobulin A (IgA) Vasculitis Market

• 17.1. Germany Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immunoglobulin A (IgA) Vasculitis Market

• 18.1. France Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immunoglobulin A (IgA) Vasculitis Market

• 19.1. Italy Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immunoglobulin A (IgA) Vasculitis Market

• 20.1. Spain Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market

• 21.1. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market Overview
• 21.2. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immunoglobulin A (IgA) Vasculitis Market

• 22.1. Russia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immunoglobulin A (IgA) Vasculitis Market

• 23.1. North America Immunoglobulin A (IgA) Vasculitis Market Overview
• 23.2. North America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immunoglobulin A (IgA) Vasculitis Market

• 24.1. USA Immunoglobulin A (IgA) Vasculitis Market Overview
• 24.2. USA Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immunoglobulin A (IgA) Vasculitis Market

• 25.1. Canada Immunoglobulin A (IgA) Vasculitis Market Overview
• 25.2. Canada Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immunoglobulin A (IgA) Vasculitis Market

• 26.1. South America Immunoglobulin A (IgA) Vasculitis Market Overview
• 26.2. South America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immunoglobulin A (IgA) Vasculitis Market

• 27.1. Brazil Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immunoglobulin A (IgA) Vasculitis Market

• 28.1. Middle East Immunoglobulin A (IgA) Vasculitis Market Overview
• 28.2. Middle East Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immunoglobulin A (IgA) Vasculitis Market

• 29.1. Africa Immunoglobulin A (IgA) Vasculitis Market Overview
• 29.2. Africa Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immunoglobulin A (IgA) Vasculitis Market Competitive Landscape And Company Profiles

• 30.1. Immunoglobulin A (IgA) Vasculitis Market Competitive Landscape
• 30.2. Immunoglobulin A (IgA) Vasculitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Immunoglobulin A (IgA) Vasculitis Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Indraprastha Medical Corporation Limited
• 31.3. Intas Pharmaceuticals Ltd
• 31.4. Mayo Clinic
• 31.5. Biogen Inc.
• 31.6. Chugai Pharmaceutical Co. Ltd.
• 31.7. The Cleveland Clinic Foundation
• 31.8. Zydus Lifesciences Limited
• 31.9. CSL Behring
• 31.10. Artemis Medicare Services Limited
• 31.11. Biocad Biotechnology Company
• 31.12. Biotest AG
• 31.13. Kauvery Hospitals Private Limited
• 31.14. Sheikh Shakhbout Medical City
• 31.15. Reliance Life Sciences Pvt. Ltd

32. Global Immunoglobulin A (IgA) Vasculitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immunoglobulin A (IgA) Vasculitis Market

34. Recent Developments In The Immunoglobulin A (IgA) Vasculitis Market

35. Immunoglobulin A (IgA) Vasculitis Market High Potential Countries, Segments and Strategies

• 35.1 Immunoglobulin A (IgA) Vasculitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immunoglobulin A (IgA) Vasculitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immunoglobulin A (IgA) Vasculitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer